
This study explores the effects of combining intravenous (IV) iron treatment with sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure patients with reduced ejection fraction (HFrEF) and iron deficiency. The researchers matched two groups of patients (60 each) based on age and sex, one using SGLT2i alongside IV iron and the other using IV iron alone. Results showed that those using SGLT2i experienced greater hemoglobin and hematocrit levels. However, there were no significant differences in iron biomarkers or other outcomes like natriuretic peptides or kidney function. These findings suggest that combining these treatments might enhance the erythropoietic response.
Like
Save
Share